Mephedrone

4-methylmethcathinone

6Node page

what any key link opens

psx:substance/mephedrone/value/duration/oral/total@1

valuereferenced by edges — no row of its own

derived from · upstream

derived_fromduration · oral · totalpsx:substance/mephedrone/proposal/duration/b8dc0f3b-489c-49db-b3e9-337cb8107504

feeds · downstream

none recorded

psx:substance/mephedrone/value/duration/oral/total@1
└─ derived_from  proposal/duration/b8dc0f3b-489c-49db-b3e9-337cb8107504  duration · oral · total

indented by distance from this node, not by parentage

1Provenance card

the boundary, as counts

Sources

4137 with DOI

4 strong · 31 moderate · 6 weak

Compilations

12026-04-20T23:32:24.316Z

pipeline-v5 · prompt hash not recorded — run predates 2026-09

Decisions

78last ruled 2026-06-04

0 awaiting a ruling

Issued documents

42026-10-19T20:32:45.725Z

notice · info card · emergency

Searches

210 with no results

queries and counts on the build

Claims checked

1234 supported

4 supported · 119 not

Correspondence

0received

consent field ships in Phase 4

Edges

365

derivations recorded for this entity

Complete over 41 sources, 1 compilation, and 78 decisions.Not here: the private journal (never).Working material — drafts, discards, unsupported claims — is listed below and readable on the working page.Cite: psychedex.org/substances/mephedrone/archive

2Build

one panel per compilation run

generation run 2026-04-20

80 min completedmodel pipeline-v5plan not recordedrun/5d640c3d…

Selection

results seen108

selected by the model47

consumed as sources41

Verification

claims checked123

supported4

partially supported0

not supported0

inconclusive119

record
seen / partial
working

The model's own caveats

none raised on this run

Reproduce

inputs: 41 source keys (listed under Sources)
plan: not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
model: pipeline-v5
streams: none — agent transcripts are persisted from 2026-09 onward

21 searches — query, source, results, what was kept and why

21 searches for this run
#	source	query	seen	kept	rationale
1	PubChem	mephedrone	1	1	Primary chemical identity data for mephedrone
2	ClinicalTrials.gov	mephedrone	4	2	Human pharmacology Phase 1 trials directly relevant to mephedrone dosing, abuse liability, and alcohol interactions
3	OpenAlex	mephedrone 4-methylmethcathinone pharmacology	15	8	High-citation landmark papers covering pharmacology, clinical toxicology, and mechanism of action
4	PubMed	mephedrone toxicity overdose case report adverse effects	3	2	Toxicology case reports directly relevant to mephedrone safety
5	PubMed	mephedrone pharmacology mechanism dopamine serotonin transporter	9	6	Core pharmacology papers with binding data and mechanism of action
6	PubMed	mephedrone dependence addiction abuse potential self-administration	1	1	—
7	PubMed	PMID 21072502, 21810934, 20358417 fetch	3	3	—
8	PubMed	mephedrone human pharmacokinetics metabolism bioavailability	2	1	—
9	PubMed	mephedrone subjective effects human study clinical trial	3	3	—
10	PubMed	mephedrone deaths fatalities post-mortem forensic	3	3	—
11	ClinicalTrials.gov	mephedrone	4	2	—
12	Erowid/WebSearch	mephedrone legal status scheduling US UK Germany Australia	10	2	—
13	WebSearch	mephedrone first synthesis 1929 Saem de Burnaga Sanchez history	10	1	—
14	PubMed	mephedrone cardiovascular cardiac effects blood pressure	5	4	—
15	OpenAlex	DOI 10.1111/j.1476-5381.2012.02145.x (Simmler 2012)	1	1	—
16	PubMed	mephedrone pharmacokinetics metabolites nor-mephedrone dihydromephedrone urine	2	2	—
17	Crossref/verify_doi	DOI 10.1007/s13181-011-0193-z	1	1	—
18	WebSearch/Erowid	mephedrone legal status jurisdictions	10	1	—
19	WebSearch	mephedrone SMILES CAS melting point physical properties	10	1	—
20	PubMed	PMID 22778288 serotonin syndrome mephedrone	1	1	—
21	WebSearch	mephedrone tramadol fatal interaction serotonin case report	10	1	—

123 claims by section — every cited sentence, checked against its source

safety42 · 4 ok

Serotonin syndrome has been documented from mephedrone alonesupported
Principal substance mephedrone. Became hyperthermic, deteriorated over next hour. Appropriate treatment for serotonin syndrome led to sustained recovery over 15h. bcr.04.2010.2925
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
A 22-year-old male presented with tachycardia, diaphoresis, hypertonia, hyperreflexia, clonus, and hyperthermia following mephedrone ingestion; progressive deterioration occurred over the first hour, with sustained recovery over 15 hours under appropriate managementsupported
22-year-old male presented with tachycardia, diaphoresis, hypertonia, hyper-reflexia and clonus. Principal substance mephedrone. Became hyperthermic, deteriorated over next hour. Appropriate treatment for serotonin syndrome led to sustained recovery over 15h. bcr.04.2010.2925
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Mephedrone alone can precipitate serotonin syndrome; co-administration with SSRIs, SNRIs, MAOIs, tramadol, lithium, or triptans elevates this risk substantiallysupported
Principal substance mephedrone. Became hyperthermic, deteriorated over next hour. Appropriate treatment for serotonin syndrome led to sustained recovery over 15h. bcr.04.2010.2925
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Mephedrone alone causes serotonin syndrome at recreational doses.supported
Principal substance mephedrone. Became hyperthermic, deteriorated over next hour. Appropriate treatment for serotonin syndrome led to sustained recovery over 15h. bcr.04.2010.2925
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →

pharmacology20 · 0 ok

Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →

neuroscience16 · 0 ok

Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →

summary14 · 0 ok

Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →

receptor-pharmacology8 · 0 ok

Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →

pharmacokinetic-detail6 · 0 ok

Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →

comparative-pharmacology5 · 0 ok

Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →

history5 · 0 ok

Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →

clinical-evidence3 · 0 ok

Claim in clinical-evidence — inconclusiveinconclusiveworking →
Claim in clinical-evidence — inconclusiveinconclusiveworking →
Claim in clinical-evidence — inconclusiveinconclusiveworking →

chemistry2 · 0 ok

Claim in chemistry — inconclusiveinconclusiveworking →
Claim in chemistry — inconclusiveinconclusiveworking →

effects-overview2 · 0 ok

Claim in effects-overview — inconclusiveinconclusiveworking →
Claim in effects-overview — inconclusiveinconclusiveworking →

3Sources

41 consumed · sorted by year · feeds = sections resting on it

Sources 1 to 30
year	source	tier	status	feeds
2025	Chemsex-related deaths in the United Kingdom (2017-2022): A review of the Forensic Toxicology dataTyler M, Ward L, Grosse S · Forensic Science Internationaldoi:10.1016/j.forsciint.2025.112553	moderate	consumed	2 sections
2024	SMILES and physical properties of mephedrone (CID 45266826)PubChem/Chemsrcurl:f0071bcdab06c69f	weak	consumed	cited only
2023	Mephedrone induces partial release at human dopamine transporters but full release at human serotonin transportersMayer FP, Niello M, Bulling S, et al. · Neuropharmacologydoi:10.1016/j.neuropharm.2023.109704	moderate	consumed	4 sections
2023	Neurochemical and Cardiovascular Effects of 4-Chloro Ring-Substituted Synthetic Cathinones in RatsChojnacki MR, Thorndike EB, Partilla JS, et al. · Journal of Pharmacology and Experimental Therapeuticsdoi:10.1124/jpet.122.001478	moderate	consumed	1 section
2021	Acute Pharmacological Effects of Oral and Intranasal Mephedrone: An Observational Study in HumansPapaseit E, Olesti E, Perez-Mana C, et al. · Pharmaceuticalsdoi:10.3390/ph14020100	moderate	consumed	4 sections
2021	Pharmacokinetics of Mephedrone and Its Metabolites in Whole Blood and Plasma after Controlled Intranasal Administration to Healthy Human VolunteersCzerwinska J, Parkin MC, George C, et al. · Journal of Analytical Toxicologydoi:10.1093/jat/bkaa134	moderate	consumed	1 section
2020	Designer drugs: mechanism of action and adverse effectsLuethi D, Liechti ME · Archives of Toxicologydoi:10.1007/s00204-020-02693-7	strong	consumed	1 section
2020	Synthetic psychoactive cathinones: hypothermia and reduced lethality compared to methamphetamine and MDMAMuskiewicz DE, Resendiz-Gutierrez F, Issa O, Hall FS · Pharmacology, Biochemistry and Behaviordoi:10.1016/j.pbb.2020.172871	moderate	consumed	1 section
2019	Dose-Response Pharmacological Study of Mephedrone and Its Metabolites: Pharmacokinetics, Serotoninergic Effects, and Impact of CYP2D6 Genetic VariationOlesti E, Farre M, Carbo ML, et al. · Clinical Pharmacology and Therapeuticsdoi:10.1002/cpt.1417	strong	consumed	4 sections
2019	Mephedrone and Alcohol Interactions in HumansPapaseit E, Perez-Mana C, de Sousa Fernandes Perna EB, et al. · Frontiers in Pharmacologydoi:10.3389/fphar.2019.01588	strong	consumed	4 sections
2019	Polytox synthetic cathinone abuse: role for organic cation transporter 3Mayer FP, Schmid D, Holy M, Daws LC, Sitte HH · Neurochemistry Internationaldoi:10.1016/j.neuint.2018.09.008	moderate	consumed	4 sections
2018	Neuropharmacology of Synthetic CathinonesBaumann MH, Walters HM, Niello M, Sitte HH · Handbook of Experimental Pharmacologydoi:10.1007/164_2018_178	moderate	consumed	2 sections
2017	GC-MS Quantification Method for Mephedrone in Plasma and Urine: Application to Human PharmacokineticsOlesti E, Pujadas M, Papaseit E, et al. · Journal of Analytical Toxicologydoi:10.1093/jat/bkw120	moderate	consumed	2 sections
2017	Neurotoxicology of Synthetic Cathinone AnalogsAngoa-Perez M, Anneken JH, Kuhn DM · Current Topics in Behavioral Neurosciencesdoi:10.1007/7854_2016_21	moderate	consumed	1 section
2017	Pharmacokinetics of Mephedrone and Its Metabolites in Human by LC-MS/MSOlesti E, Farre M, Papaseit E, et al. · The AAPS Journaldoi:10.1208/s12248-017-0132-2	moderate	consumed	1 section
2017	Stereoselective Differences between the Reinforcing and Motivational Effects of Cathinone-Derived 4-Methylmethcathinone (Mephedrone) in Self-Administering RatsPhilogene-Khalid HL, Simmons SJ, Nayak S, et al. · ACS Chemical Neurosciencedoi:10.1021/acschemneuro.7b00212	moderate	consumed	3 sections
2016	Human Pharmacology of Mephedrone in Comparison with MDMAPapaseit E, Pérez-Mañá C, Mateus JA, et al. · Neuropsychopharmacologydoi:10.1038/npp.2016.75	strong	consumed	5 sections
2015	Mephedrone related fatalities: a reviewBusardo FP, Kyriakou C, Napoletano S, Marinelli E, Zaami S · European Review for Medical and Pharmacological Sciencespmid:26502870	moderate	consumed	1 section
2015	Self-reported prevalence of dependence of MDMA compared to cocaine, mephedrone and ketamine among a sample of recreational poly-drug usersUosukainen H, Tacke U, Winstock AR · International Journal on Drug Policydoi:10.1016/j.drugpo.2014.07.004	moderate	consumed	1 section
2014	A 3-year review of new psychoactive substances in caseworkElliott S, Evans J · Forensic Science Internationaldoi:10.1016/j.forsciint.2014.04.017	moderate	consumed	2 sections
2014	Abuse-related and abuse-limiting effects of methcathinone and the synthetic bath salts cathinone analogs MDPV, methylone and mephedrone on intracranial self-stimulation in ratsBonano JS, Glennon RA, De Felice LJ, Banks ML, Negus SS · Psychopharmacologydoi:10.1007/s00213-013-3223-5	moderate	consumed	2 sections
2014	Manganese-enhanced magnetic resonance imaging reveals differential long-term neuroadaptation after methamphetamine and mephedroneden Hollander B, Dudek M, Ojanpera I, et al. · International Journal of Neuropsychopharmacologydoi:10.1093/ijnp/pyu106	moderate	consumed	1 section
2013	Bath salts intoxication: a case seriesImam SF, Patel H, Mahmoud M, et al. · Journal of Emergency Medicinedoi:10.1016/j.jemermed.2013.04.017	weak	consumed	1 section
2013	Changes in ambient temperature differentially alter the thermoregulatory, cardiac and locomotor stimulant effects of 4-methylmethcathinone (mephedrone)Miller ML, Creehan KM, Angrish D, et al. · Drug and Alcohol Dependencedoi:10.1016/j.drugalcdep.2012.07.003	moderate	consumed	2 sections
2013	Differential effects of cathinone compounds and MDMA on body temperature in the rat, and pharmacological characterization of mephedrone-induced hypothermiaShortall SE, Green AR, Swift KM, Fone KC, King MV · British Journal of Pharmacologydoi:10.1111/j.1476-5381.2012.02236.x	moderate	consumed	2 sections
2013	In vitro metabolism studies on mephedrone and analysis of forensic casesPedersen AJ, Reitzel LA, Johansen SS, Linnet K · Drug Testing and Analysisdoi:10.1002/dta.1369	moderate	consumed	3 sections
2013	Long-term cognitive and neurochemical effects of bath salt designer drugs methylone and mephedroneden Hollander B, Rozov S, Linden AM, et al. · Pharmacology, Biochemistry and Behaviordoi:10.1016/j.pbb.2012.10.006	moderate	consumed	2 sections
2013	Mephedrone (4-methylmethcathinone) supports intravenous self-administration in Sprague-Dawley and Wistar ratsAarde SM, Angrish D, Barlow DJ, et al. · Addiction Biologydoi:10.1111/adb.12038	moderate	consumed	2 sections
2012	Comparative neuropharmacology of three psychostimulant cathinone derivatives: butylone, mephedrone and methyloneLopez-Arnau R, Martinez-Clemente J, Pubill D, Escubedo E, Camarasa J · British Journal of Pharmacologydoi:10.1111/j.1476-5381.2012.01998.x	moderate	consumed	2 sections
2012	Effect of ambient temperature on the thermoregulatory and locomotor stimulant effects of 4-methylmethcathinone in Wistar and Sprague-Dawley ratsWright MJ, Angrish D, Aarde SM, et al. · PLoS ONEdoi:10.1371/journal.pone.0044652	moderate	consumed	2 sections

Show all 41 sources — 11 more

Sources 31 to 41
year	source	tier	status	feeds
2012	Mephedrone, a new designer drug of abuse, produces acute hemodynamic effects in the ratMeng H, Cao J, Kang J, et al. · Toxicology Lettersdoi:10.1016/j.toxlet.2011.10.010	moderate	consumed	3 sections
2012	Pharmacological characterization of designer cathinones in vitroSimmler LD, Buser TA, Donzelli M, et al. · British Journal of Pharmacologydoi:10.1111/j.1476-5381.2012.02145.x	moderate	consumed	3 sections
2012	The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissueBaumann MH, Ayestas MA, Partilla JS, et al. · Neuropsychopharmacologydoi:10.1038/npp.2011.304	moderate	consumed	7 sections
2011	4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuseHadlock GC, Webb KM, McFadden LM, et al. · Journal of Pharmacology and Experimental Therapeuticsdoi:10.1124/jpet.111.184119	moderate	consumed	3 sections
2011	Mephedrone (4-methylmethcathinone; 'meow meow'): chemical, pharmacological and clinical issuesSchifano F, Albanese A, Fergus S, et al. · Psychopharmacologydoi:10.1007/s00213-010-2070-x	moderate	consumed	2 sections
2011	Mephedrone Legal Status by Jurisdiction (Erowid)Erowidurl:ef3c1c9e5932c845	weak	consumed	cited only
2011	Mephedrone, compared with MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and 5-HT levels in nucleus accumbens of awake ratsKehr J, Ichinose F, Yoshitake S, et al. · British Journal of Pharmacologydoi:10.1111/j.1476-5381.2011.01499.x	moderate	consumed	3 sections
2011	Mephedrone: use, subjective effects and health risksWinstock A, Mitcheson L, Ramsey J, et al. · Addictiondoi:10.1111/j.1360-0443.2011.03502.x	moderate	consumed	2 sections
2010	Multiple-drug toxicity caused by the coadministration of 4-methylmethcathinone (mephedrone) and heroinDickson AJ, Vorce SP, Levine B, Past MR · Journal of Analytical Toxicologypmid:20406541	weak	consumed	1 section
2010	Recreational use of mephedrone (4-methylmethcathinone, 4-MMC) with associated sympathomimetic toxicityWood DM, Davies S, Puchnarewicz M, et al. · Journal of Medical Toxicologydoi:10.1007/s13181-010-0018-5	weak	consumed	1 section
2010	The serotonin syndrome as a result of mephedrone toxicityGarrett G, Sweeney M · BMJ Case Reportsdoi:10.1136/bcr.04.2010.2925	weak	consumed	1 section

4Docket

one filing per activity — decisions, correspondence, reports

0012026-04-20revisionRevision 1
Initial LLM generation (v5 pipeline, wiki)
psx:substance/mephedrone/version/1
0022026-04-21proposaldose_tier · threshold
psx:substance/mephedrone/proposal/dose_tier/18476dad-fe3d-4fad-bb8c-7fcb895c47c8
0032026-04-21proposaldose_tier · light
psx:substance/mephedrone/proposal/dose_tier/0bf83c08-9e22-4dbd-a415-a63ae40d5717
0042026-04-21proposaldose_tier · common
psx:substance/mephedrone/proposal/dose_tier/86c90100-29a2-413b-8d19-7ab8eeb0e4cb
0052026-04-21proposaldose_tier · strong
psx:substance/mephedrone/proposal/dose_tier/7edda3a2-53d3-45f4-a416-19d9c3e5e3e7
0062026-04-21proposaldose_tier · heavy
psx:substance/mephedrone/proposal/dose_tier/64106fe0-c2ff-4ce3-be83-cb1c4ab87f2c
0072026-04-21proposaltimeline · oral · onset
psx:substance/mephedrone/proposal/timeline/adc2953f-73e6-4fce-aea8-565ce876212b
0082026-04-21proposaltimeline · oral · come_up
psx:substance/mephedrone/proposal/timeline/f81c668a-c540-4768-9264-eb102b92ebd2
0092026-04-21proposaltimeline · oral · peak
psx:substance/mephedrone/proposal/timeline/fdcc44c5-2a51-4c8a-8a2b-631fc91feb44
0102026-04-21proposaltimeline · oral · plateau
psx:substance/mephedrone/proposal/timeline/9c0a2c82-7c3f-4f64-b9b0-cbdcb6f0ae54
0112026-04-21proposaltimeline · oral · resolution
psx:substance/mephedrone/proposal/timeline/2c4a5dba-6caf-46a5-a388-f999fd141f35
0122026-04-21proposaltimeline · oral · afterglow
psx:substance/mephedrone/proposal/timeline/06afd8b2-01cc-42ca-9acd-ae10bd6875a5
0132026-04-21proposaltimeline · insufflated · onset
psx:substance/mephedrone/proposal/timeline/6e6173fe-1946-4ccc-b62e-a63506851182
0142026-04-21proposaltimeline · insufflated · come_up
psx:substance/mephedrone/proposal/timeline/9777d2d7-968e-4375-8e02-9fbebb0f8b0d
0152026-04-21proposaltimeline · insufflated · peak
psx:substance/mephedrone/proposal/timeline/71a1ae35-10a9-4d99-9d15-0bac1d6340b5
0162026-04-21proposaltimeline · insufflated · resolution
psx:substance/mephedrone/proposal/timeline/70dc486c-aff3-47b8-bd82-eeb8dad5b658
0172026-04-21proposaltimeline · insufflated · afterglow
psx:substance/mephedrone/proposal/timeline/5cd9cb54-e582-47a6-820a-a9f1f9c8af3a
0182026-04-21proposaltoxicity
psx:substance/mephedrone/proposal/toxicity/cc0cf8fb-3eab-4f59-95d2-2a9d234c1ad8
0192026-04-21proposaldependence · full
psx:substance/mephedrone/proposal/dependence/bb343b7d-f960-4336-924f-ae5be035ef48
0202026-04-21proposalwithdrawal
psx:substance/mephedrone/proposal/withdrawal/f24f75e5-994d-4756-ad0e-70debbe42e54
0212026-04-21proposaltolerance
psx:substance/mephedrone/proposal/tolerance/a487c71b-7a2e-4e72-84ab-e4eeb1a69b33
0222026-04-21proposaldosage · oral
psx:substance/mephedrone/proposal/dosage/eebc9733-b6d2-40a5-8131-223ea0ec0737
0232026-04-21proposaldosage · insufflated
psx:substance/mephedrone/proposal/dosage/0480eba9-3b2a-4d89-9a67-1089c2b21033
0242026-04-21proposalduration · oral · onset
psx:substance/mephedrone/proposal/duration/53883f28-d246-4a2e-9fe5-9f7c1a49413c
0252026-04-21proposalduration · oral · come_up
psx:substance/mephedrone/proposal/duration/fb77e873-ea6c-4030-bd25-1f4680acc22a
0262026-04-21proposalduration · oral · peak
psx:substance/mephedrone/proposal/duration/7fab945c-682d-41eb-9e2f-68821f1e6cb3
0272026-04-21proposalduration · oral · offset
psx:substance/mephedrone/proposal/duration/21a05a53-2ab2-4688-8dbd-a4381bfa9b75
0282026-04-21proposalduration · oral · total
psx:substance/mephedrone/proposal/duration/c5206a6e-a958-4650-90b1-d35284649059
0292026-04-21proposalduration · oral · aftereffects
psx:substance/mephedrone/proposal/duration/9275130a-28a9-4355-9225-834dc3933bef
0302026-04-21proposalduration · insufflated · onset
psx:substance/mephedrone/proposal/duration/41e837f1-0368-4b4a-a76f-520c050d8536
0312026-04-21proposalduration · insufflated · come_up
psx:substance/mephedrone/proposal/duration/c0440b94-4bd1-413a-b2d2-9e3f60337f60
0322026-04-21proposalduration · insufflated · peak
psx:substance/mephedrone/proposal/duration/adbe4c4b-588c-4e99-804b-6a982c01cff9
0332026-04-21proposalduration · insufflated · offset
psx:substance/mephedrone/proposal/duration/6e6dd605-4022-4166-9be5-4cada68272a5
0342026-04-21proposalduration · insufflated · total
psx:substance/mephedrone/proposal/duration/9e40f3c5-96e8-4431-9305-742d484a77cd
0352026-04-21proposalduration · insufflated · aftereffects
psx:substance/mephedrone/proposal/duration/87f11dc0-215d-48b2-9ea1-e801880042fb
0362026-06-04proposal42 value proposals approved together
one review action inferred from a shared reviewer and instant — the graph records one activity per proposal
42 items in this filing
- dose_tier · light
- dose_tier · common
- dose_tier · strong
- dose_tier · heavy
- timeline · oral · onset
- timeline · oral · come_up
- timeline · oral · peak
- timeline · oral · plateau
- timeline · oral · resolution
- timeline · oral · afterglow
- timeline · insufflated · onset
- timeline · insufflated · come_up
- timeline · insufflated · peak
- timeline · insufflated · plateau
- timeline · insufflated · resolution
- timeline · insufflated · afterglow
- toxicity
- dependence · full
- withdrawal
- tolerance
- dosage · oral
- dosage · insufflated
- duration · oral · onset
- duration · oral · come_up
- duration · oral · peak
- duration · oral · offset
- duration · oral · total
- duration · oral · aftereffects
- duration · insufflated · onset
- duration · insufflated · come_up
- duration · insufflated · peak
- duration · insufflated · offset
- duration · insufflated · total
- duration · insufflated · aftereffects
- contraindication · metabolic
- contraindication · cardiovascular
- contraindication · psychiatric
- contraindication · other
- contraindication · other
- contraindication · pregnancy_breastfeeding
- contraindication · psychiatric
psx:substance/mephedrone/proposal/dose_tier/46f76ec0-8d04-4a2c-86cf-ff1de127f070
0372026-06-04publicationPublication — backfill
psx:substance/mephedrone/pub/e4b45656-8984-4967-a869-d24533e60737

5Issued documents

what the notice, info card and emergency page said, by hash

Issued documents
document	content hash	issued	from version	superseded
info_card	1e3038aebd826927a596964c…	2026-10-19 20:32	Revision 1	current
emergency	47cf1475db8db7f236c6a01a…	2026-09-04 04:30	Revision 1	current
info_card	29319cdac70f1bced1950cf2…	2026-09-04 04:30	Revision 1	superseded2026-10-19
notice	6092867e67a34b1ffc5c2d45…	2026-09-04 04:30	Revision 1	current

Mephedrone

6Node page

derived from · upstream

feeds · downstream

1Provenance card

2Build

generation run 2026-04-20

research→

draft→

audit→

verify→

simplify→

publish

Selection

Verification

The model's own caveats

Reproduce

3Sources

4Docket

5Issued documents

research

draft

audit

verify

simplify